Small molecule regulation of normal and leukemic stem cells

Area of Science:

• Hematology
• Stem Cell Biology
• Pharmacology

Background:

• Hematopoietic stem and progenitor cell (HSPC) transplantation is crucial for treating hematological diseases.
• Transplant success is linked to the number of infused cells, a challenge in cord blood transplants.
• Expanding HSPCs ex-vivo can improve engraftment and reduce complications.

Purpose of the Study:

• To review recent findings on small molecules regulating normal and leukemic stem cells.
• To explore the potential of small molecules in enhancing hematopoietic stem cell transplantation.
• To provide insights into the basic science and clinical implications of small molecule regulators.

Main Methods:

• Review of recent scientific literature on small molecule regulators of stem cells.
• Analysis of high-throughput screening data for compounds active on hematopoietic cells.
• Discussion of identified small molecules, including StemRegenin1 and UM171.

Main Results:

• Identification of two potent small molecule series, StemRegenin1 and UM171, that expand HSPCs.
• StemRegenin1, an aryl hydrocarbon receptor antagonist, is active on primitive progenitors and leukemic stem cells (LSCs).
• UM171 demonstrates expansion of long-term normal hematopoietic stem cells (HSCs).

Conclusions:

• Small molecules are clinically valuable tools for expanding HSPCs.
• These molecules offer potential for understanding self-renewal regulatory networks in human HSCs.
• Further research into small molecules can advance stem cell therapies and disease treatment.